about
Determination of Phenotypic Resistance Cutoffs From Routine Clinical DataA potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.HIV protease inhibitors: recent clinical trials and recommendations on use.New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.Darunavir: a review of its use in the management of HIV-1 infection.Use of darunavir and enfuvirtide in a pregnant woman.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Darunavir: in the treatment of HIV-1 infection.
@en
Darunavir: in the treatment of HIV-1 infection.
@nl
type
label
Darunavir: in the treatment of HIV-1 infection.
@en
Darunavir: in the treatment of HIV-1 infection.
@nl
prefLabel
Darunavir: in the treatment of HIV-1 infection.
@en
Darunavir: in the treatment of HIV-1 infection.
@nl
P1433
P1476
Darunavir: in the treatment of HIV-1 infection.
@en
P2093
Caroline Fenton
P304
P356
10.2165/00003495-200767180-00010
P577
2007-01-01T00:00:00Z
P6179
1038136415